The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Rachel Rau, Texas Children's Hospital, Houston, US. We asked, How does MRD guide therapeutic decisions in ALL?
How does MRD guide therapeutic decisions in ALL?
Rau begins by outlining the two main modalities with which MRD is measured, multiple parameter flow cytometry or PCR. Rau goes on to explain when to test MRD and the correlation between a poor prognosis and a higher MRD. She discusses high risk patients in ALL and the possible treatment options for patients who are still MRD positive after consolidation. Finally, Rau highlights that the future may hold further investigation into more sensitive assays, to further risk stratify patients, such as the clonoSEQ assay.